Scilex Holding Company Regains Nasdaq Compliance
PALO ALTO, Calif. – Scilex Holding Company (NASDAQ: SCLX) is excited to announce that it has regained compliance with Nasdaq Listing Rule 5250(c)(1). This resurgence comes on the heels of the successful filing of its Quarterly Report on Form 10-Q for the quarter concluding September 30, 2024. The company's focus remains steadfast on developing non-opioid pain management solutions aimed at addressing both acute and chronic pain.
Innovative Approaches to Pain Management
Scilex is dedicated to revolutionizing pain management through innovative products that target areas of high unmet need. Its mission encompasses the acquisition, development, and commercialization of cutting-edge therapies that help manage pain effectively while minimizing reliance on opioids. These efforts are pivotal as the company prepares to introduce its proposed joint venture with IPMC Company to explore treatment options for neurodegenerative and cardiometabolic diseases.
Product Portfolio and Market Impact
Currently, Scilex boasts an impressive lineup of commercial products designed to enhance patient outcomes. These include ZTlido®, an FDA-approved lidocaine topical system aimed at treating neuropathic pain related to postherpetic neuralgia, ELYXYB®, an innovative oral migraine treatment that is the first of its kind approved by the FDA for acute migraine attacks, and Gloperba®, a liquid colchicine formulation targeting painful gout flares as its prophylactic treatment.
Pioneering Future Developments
Looking to the future, Scilex has an exciting pipeline of product candidates under development. This includes SP-102 (SEMDEXA™), a viscous gel corticosteroid formulation aimed at alleviating sciatica through epidural injections. Scilex has achieved notable progress with SP-102, having completed a Phase 3 clinical study and receiving Fast Track designation from the FDA. In addition, SP-103, a next-generation formulation of ZTlido®, recently completed a Phase 2 trial, signaling impressive potential for acute pain management.
Commitment to Patient Care
At the heart of Scilex's strategy is its unwavering commitment to advancing patient care. The company prioritizes research into therapies that not only manage pain effectively but also contribute to improved quality of life for patients managing chronic conditions. With a robust pipeline and innovative products, Scilex endeavors to ensure that individuals have access to safe and effective pain management options.
Moreover, Scilex's partnership with Semnur Pharmaceuticals, Inc., further amplifies its mission to develop non-opioid pain management therapies. Semnur's focus on the development of SP-102 (SEMDEXA™), a non-opioid product tailored for patients suffering from chronic radicular pain, represents a significant advancement in the field and complements Scilex's overall objectives.
Engagement and Investor Relations
Scilex remains committed to transparency and engagement with investors and stakeholders. The company's recent compliance with Nasdaq listing standards reflects its fiscal responsibility and strategic positioning within the pharmaceutical industry. Investors are encouraged to stay informed about Scilex’s developments and product launches as part of its growth trajectory in the marketplace.
Frequently Asked Questions
What is Scilex Holding Company known for?
Scilex Holding Company is primarily known for its focus on developing non-opioid pain management products and its innovative therapeutic solutions for treating acute and chronic pain.
How does Regaining Nasdaq Compliance affect the company?
Regaining compliance with Nasdaq Listing Rule 5250(c)(1) signifies Scilex's commitment to fiscal responsibility and allows it to maintain its listing on the Nasdaq stock exchange, providing investment confidence to its shareholders.
What products are included in Scilex’s portfolio?
Scilex’s portfolio includes ZTlido®, ELYXYB®, and Gloperba®, each developed to manage different types of pain effectively and safely.
What is the significance of the joint venture with IPMC Company?
The joint venture with IPMC Company aims to explore and develop new treatments that target neurodegenerative and cardiometabolic diseases, expanding Scilex's therapeutic reach and potential market impact.
How can investors stay updated on Scilex developments?
Investors can stay updated through Scilex's official website and investor relations communications, which provide insights into ongoing clinical trials, product launches, and financial reporting.
